Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
SB 202190
Cat No.
CEI-0151
Description
SB 202190 (FHPI) can potently inhibit p38alpha and p38beta with IC50 of 50 nM and 100 nM.
CAS No.
152121-30-7
Molecular Weight
331.34
Purity
>99%
Storage
2 years at -20 centigrade
Targets
p38alpha, p38beta
Molecular Formula
C20H14N3OF
Chemical Name
4-(4-(4-fluorophenyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl)phenol
Solubility
DSMO 66 mg/mL Water
In vitro
SB 202190 significantly inhibits both basal and anti-Fas antibody-induced MAPKAPK 2 activity in a dose-dependent manner. SB 202190 strongly inhibits UVB induced COX-2 protein expression in HaCaT cells, and markedly inhibits UVB induced cox-2 mRNA. SB 202190 treatment enhances the growth of THP-1 and MV4-11 cells. SB 202190 increases the phosphorylation of c-Raf and ERK, suggesting that Ras-Raf-MEK-mitogen-activated protein kinase (MAPK) pathway activation is involved in the leukemia cell growth induced by SB 202190.
In vivo
In the endotoxin model of sepsis, SB 202190 treatment produces a statistically significant survival benefit compared with control.
Download
Download Datasheet